ArticleBMC geriatrics2023
Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study.
Article in BMC geriatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Associations between gut microbiota and sarcopenia or its defining parameters in older adults: A systematic review.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Health Care-Related Determinants of First-Time Long-Term Care Need in Older Adults in Germany: Retrospective Cohort Study Using Claims Data.Interactive journal of medical research · 2026Article
- Exploring the Association of Polypharmacy and Depressive Symptoms with Sarcopenia in Older Adults.Journal of clinical medicine · 2026Article
- Metformin Partially Attenuates Simvastatin-Induced Myotoxic Responses in C2C12 Myotubes Through Metabolic Adaptation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Frailty and osteosarcopenia in older men: a hidden vulnerability.BMC geriatrics · 2026Article
- Pharmacist-Led Deprescribing Interventions for Older Adults with Polypharmacy: A Retrospective Cohort Study of Community Pharmacy Practice in Japan.Drugs & aging · 2026Article
- Assessing the risk of sarcopenia among community-dwelling older adults in Israel: a national cross-sectional survey.European geriatric medicine · 2026Article
- Medication Reduction is Associated with Improved Activities of Daily Living and Muscle Strength in Post-Stroke Patients with Polypharmacy.JMA journal · 2026Article
- Sarcopenia in older adults admitted to acute medical unit: a prospective observational study of feasibility and clinical outcomes.Frontiers in medicine · 2026Article
- Vitamin B deficiency and sarcopenia: an integrated narrative review of metabolic, inflammatory, endoplasmic reticulum stress, and myokine signaling pathways.Journal of Yeungnam medical science · 2026Article
- Polypharmacy and associated factors in older adults living in communities: a comparative study using the Social Frailty Score and Kihon Checklist.Journal of rural medicine : JRM · 2025Article
- Whether a polyethylene terephthalate bottle cap can be opened could serve as a common indicator for locomotive syndrome, frailty and sarcopenia.Geriatrics & gerontology international · 2025Article
- Coexistence of Nocturia and Frailty and Its Effect on Polypharmacy in Community-Dwelling Older Adults.Cureus · 2025Article
- Anticholinergic burden quantified using the Japanese risk scale as a predictor of frailty and sarcopenia among community-dwelling older adults: A 9-year Kashiwa cohort study.Geriatrics & gerontology international · 2025Article
- Development of a Predictive Model for Potentially Inappropriate Medications in Older Patients with Cardiovascular Disease.Drugs & aging · 2024Article
- Association between Internet Use and Locomotive Syndrome, Frailty, and Sarcopenia among Community-Dwelling Older Japanese Adults.Nursing reports (Pavia, Italy) · 2024Article
- Medical care priorities of community-dwelling older adults according to three dimensions of quality of life: Quality of daily living, satisfaction and happiness from birth to death, and human vitality.Geriatrics & gerontology international · 2024Article
- Drug-related sarcopenia as a secondary sarcopenia.Geriatrics & gerontology international · 2024Review
- Redefining polypharmacy: Shifting from drug counts to patient-centered clinical appropriateness.Perspectives in clinical researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical evidence demonstrating a longitudinal association between prescribed medications and sarcopenia onset is lacking. We investigated the association of polypharmacy (the use of five or more medications) and potentially inappropriate medications (PIMs) with sarcopenia risk in community-dwelling older adults.
methodsIn this longitudinal population-based cohort study, 2,044 older residents with no long-term care needs were randomly selected from a community in Kashiwa, Japan. Baseline data collection was conducted in 2012, with follow-ups in 2013, 2014, 2016, 2018, and 2021. Prescribed medications and PIMs (drugs listed in the Screening Tool for Older Person's Appropriate Prescriptions for the Japanese or potentially muscle-wasting drugs) were identified through interviews. New-onset sarcopenia was identified according to the 2019 criteria of the Asian Working Group for Sarcopenia over a 9-year period and analyzed. We used Cox proportional hazards models to test the longitudinal association of prescribed medications with sarcopenia onset.
resultsOf the 1,549 participants without sarcopenia at baseline (mean age, 72.5 ± 5.5 years; 49.1% women; median and interquartile range, 6.0 [4.0-9.0] years), 230 experienced new-onset sarcopenia during the follow-up. After adjusting for confounders, polypharmacy combined with PIM use was strongly associated with new-onset sarcopenia (adjusted hazard ratio, 2.35; 95% confidence interval, 1.58-3.51; P < 0.001). No significant associations were observed for either PIM use or polypharmacy alone.
conclusionsPolypharmacy combined with PIM use, but not polypharmacy alone, was associated with an increased risk of new-onset sarcopenia over the 9-year follow-up period among community-dwelling older adults. Limiting polypharmacy and imposing the prescription of appropriate medications may facilitate sarcopenia prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.